2019-2020, a prosperous year under the theme of growth
The year 2019-2020 took place under the theme of growth. The IRICoR solution has benefited to a growing number of national and international researchers. IRICoR is proud to present its activity report. To consult it, click on the image.

IRICoR is very pleased to announce the appointment as of January 11, 2021 of Rémi-Martin Laberge as Vice-President, Scientific Operations and new member of IRICoR’s Management team. In this role, Dr. Laberge’s responsibilities will include ensuring, with his team, a continued follow-up of portfolio projects with support to the research teams, and identification of new opportunities in line with a […]

IRICoR is proud to welcome Ms. Hélène Grangé to its team, as Senior Manager – Contracts and Licenses.
As part of IRICoR’s business development team, Ms. Grangé will play a key role in the development and management of contracts and licenses involving IRICoR and its numerous partners in the private and public sectors. She will interact with various stakeholders both internally […]

Investment will support clinical trial in sickle cell disease
MONTREAL, Aug. 7, 2020 /CNW Telbec/ – IRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, announces a new investment in ExCellThera Inc., a clinical-stage cell and molecular medicine company which it co-founded in 2015.
IRICoR’s investment enabled ExCellThera to secure the co-funding required in connection with […]

$3M for new treatment research, a joint investment of IRICoR and the Quebec Breast Cancer Foundation
Montreal, July 14, 2020 – The pandemic has highlighted the importance of supporting scientific research in order to allow investigators to find real solutions to deal with public health issues such as COVID-19 or cancer. In this context, IRICoR and the Quebec Breast Cancer Foundation […]

During BIO Digital on June 11,  our CEO Nadine Beauger was a guest speaker at Connect with Canada, a webinar discussion with Minister Navdeep Bains (Minister of Innovation, Science and Industry),  Gordon McCauley (President and CEO AdMare BioInnovations) and Andrew Casey (CEO BIOTECanada).
The discussion explored Canadian innovation in the face of COVID-19, and the role Canada’s biotech industry will play […]

On June 11th, 2020 Nadine Beauger, President & CEO at IRICoR, will take part in a discussion session as a guest speaker at Connect with Canada presented by BIOTECanada. Along with The Honourable Minister Navdeep,Canada’s Minister of Innovation, Science and Industry, and Gordon McCauley from adMare BioInnovations, Nadine Beauger will discuss about Canada’s biotech ecosystem in the context of the […]

PARIS, France, and MONTREAL, Canada, 04 May 2020 — Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian drug discovery and research commercialization center, and Université de Montréal, today announced they entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology program.
Under the leadership of […]

 
The new issue of BIOTECanada’s Insights magazine is now available. IRICoR is proud to have collaborated on this edition. Find an article in Q&A format with selected IRICoR partners, highlighting the importance of collaboration in research and life sciences, pillar of the IRICoR business model and key to its success.
 
To read the full article, click here.
To […]

Montréal, March 19 2020 – Given the exceptional circumstances currently surrounding the COVID-19 pandemic and in compliance with the policies implemented by our governments, which have declared a state of health emergency, IRICoR management has decided to introduce certain temporary measures in order to reduce contact and the risk of transmission. To do so, all IRICoR staff members have been […]